Taoiseach launches expansion of Wage Subsidy Scheme
The Wage Subsidy Scheme gives employers financial support to encourage them to hire people with disabilities.
Advertisement
Employers can get a subsidy of between €6.30-€9.45 per hour, depending on the number of workers employed under the scheme.
The support can help cover the cost of adapting a role for the employee.
Under measures announced by Taoiseach Micheál Martin and Social Protection Minister Dara Calleary, the scheme is to be extended to the community and voluntary sector as well as the commercial state-sponsored sector.
In addition, there will be a reduction in the minimum required hours to avail of the subsidy – down from 21 to 15 hours.
Advertisement
The scheme has also been expanded beyond recruitment to include retention of people returning to work on Partial Capacity Benefit.
The subsidy rate is to be reviewed at least every three years.
Disability Minister Norma Foley and junior minister Hildegarde Naughton also addressed a launch event at Chartered Accountants House in Dublin on Wednesday.
Mr Martin said: 'Supports like this play not only a critical role in closing the employment gap for people with disabilities, reducing poverty and supporting families and communities, but also for employers in bringing new ideas, skills and knowledge to their businesses.
Advertisement
'I am committed to advancing the rights and improving the lives of people with disabilities including through removing barriers to employment.
'Supports such as this revised Wage Subsidy Scheme recognise that the perspective, talents, and contributions of people with disabilities across society add immeasurably to the quality, the richness and the diversity of all our lives.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
8 minutes ago
- Daily Mail
I am injecting my 13-year-old daughter with fat jabs. This is why I did it, the incredible impact it's already had and why hundreds of parents will follow in my footsteps
Tomorrow evening, just as she has done for the last eight months, Sarah Masterman* will take a small syringe into her 13-year-old daughter Bella's bedroom and swiftly inject medication into one of her thighs. The mother of three is happy to describe this weekly ritual as little short of a lifesaver, although it is not vital emergency medicine that Sarah is administering to her young daughter's body. It is the GLP-1 drug semaglutide, a weight-loss aid better known by brand names such as Ozempic and Wegovy. Teenage Bella is certainly a success story on that front: since Christmas, she has lost three stone, dropping from 11st 7lbs to just over 8st.
The Independent
39 minutes ago
- The Independent
Study reveals health risks of excessive screen time in teens
Excessive screen time in children and young adults significantly increases the risk of heart-related health conditions such as high blood pressure, high cholesterol, and insulin resistance. Danish researchers found that this link is particularly strong in individuals who experience reduced sleep, suggesting screen use may be displacing crucial sleep time. The study, involving over 1,000 Danish youths, revealed that each additional hour of screen time daily worsened cardiometabolic risk, with three extra hours leading to a notable increase. Machine learning identified a 'screen-time fingerprint' in blood samples, indicating biological changes that could signal long-term heart health risks from early screen habits. Experts recommend gradually reducing screen time, particularly by shifting screen use earlier in the day and prioritizing earlier and longer sleep, to mitigate these health risks.
The Guardian
an hour ago
- The Guardian
Sales of Novo Nordisk's diabetes drugs including Ozempic slow sharply
Sales of Novo Nordisk's injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of US tariffs, prompting it to cut costs and sharpen its commercial focus. The Danish drugmaker, whose booming sales of GLP-1 diabetes and obesity drugs in recent years had turned it into Europe's most valuable company, has lost nearly $100bn (£75bn) in market value since cutting its full-year sales forecast last week, when its share price slid 30% in its worst week in more than two decades. It fell a further 3% on Wednesday. On Wednesday, Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and appetite – grew by 8% in the first half of the year, down from 21% last year. Sales of obesity drugs including Wegovy increased by 56%, taking total sales 16% higher to 155bn Danish kroner (£18bn). Profit before tax climbed by 24% to 70.8bn kroner. The company has lost market share to its US rival Eli Lilly's Mounjaro, which studies have shown to be more effective, as well as cheaper versions made by generic drugmakers. It has also been hit by 'compounding' in the US, where pharmacies make up medications from ingredients, even though the US regulator declared an end to the practice recently. Novo Nordisk's outgoing chief executive, Lars Fruergaard Jørgensen, said that the copycat market had 'equal size to our business' and that compounded versions of Wegovy were sold at a 'much lower price point'. Its finance chief, Karsten Munk Knudsen, said the company was pursuing various strategies, including lawsuits against compounding pharmacies and expanding its US direct-to-consumer platform, NovoCare, launched in March. The company might also pursue 'cash sales' directly to patients elsewhere. Jørgensen said Novo Nordisk was taking measures to 'sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth'. He said it would probably not be able to avoid layoffs, but that no decision had been made. He said it would be up to Maziar Mike Doustdar, who takes over as CEO on Thursday, to make such a decision. The company is now expecting sales growth of between 8% and 14% at constant exchange rates in 2025, down sharply from its previous estimate of 13% to 21%. Novo Nordisk also disclosed that it had ditched several weight-loss drugs in development, including one that has just completed an intermediate (phase II) clinical study, 'due to portfolio considerations'. The company faces a class action lawsuit in the US from investors, who claim that it misled them with optimistic growth forecasts in the lucrative weight loss market. The UBS analyst Matthew Weston said: 'We expect GLP-1 compounders to remain in the US, which limits cash-pay uptake and leaves an uncertain outlook for US Wegovy. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion 'President Trump's proposal to reimburse GLP-1 obesity in Medicare could add significant volume uplift, but most-favoured-nation demands to offer US cash sales at European prices could significantly reduce value.' Derren Nathan, the head of equity research at Hargreaves Lansdown, said: 'Tariffs and drug pricing policy are another threat Mike Doustdar will need to tackle head-on if one of Denmark's greatest success stories is to regain its crown as Europe's most valuable company. 'The 15% blanket rate on EU imports is not necessarily the end of the story as Donald Trump dangles the prospect of levies of up to 250% on pharmaceutical imports under a separate section 232 investigation.'
